JPS57179120A - Application of snake poison for treatment of nervous system or related diseases - Google Patents

Application of snake poison for treatment of nervous system or related diseases

Info

Publication number
JPS57179120A
JPS57179120A JP5720482A JP5720482A JPS57179120A JP S57179120 A JPS57179120 A JP S57179120A JP 5720482 A JP5720482 A JP 5720482A JP 5720482 A JP5720482 A JP 5720482A JP S57179120 A JPS57179120 A JP S57179120A
Authority
JP
Japan
Prior art keywords
treatment
application
nervous system
related diseases
snake poison
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5720482A
Other languages
English (en)
Inventor
Ii Haasuto Uiriamu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPS57179120A publication Critical patent/JPS57179120A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/58—Reptiles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP5720482A 1981-04-07 1982-04-06 Application of snake poison for treatment of nervous system or related diseases Pending JPS57179120A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/251,745 US4341762A (en) 1981-04-07 1981-04-07 Use of snake venoms for treatment of neurological and related disorders

Publications (1)

Publication Number Publication Date
JPS57179120A true JPS57179120A (en) 1982-11-04

Family

ID=22953228

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5720482A Pending JPS57179120A (en) 1981-04-07 1982-04-06 Application of snake poison for treatment of nervous system or related diseases

Country Status (6)

Country Link
US (1) US4341762A (ja)
EP (1) EP0063091B1 (ja)
JP (1) JPS57179120A (ja)
DE (1) DE3273730D1 (ja)
IL (1) IL65405A (ja)
MX (1) MX7262E (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333334A (ja) * 1986-05-19 1988-02-13 ベンテツク　リサーチ　インコーポレーテツド 細胞毒性薬剤としてのクロトキシン錯体
JP2008509990A (ja) * 2004-08-16 2008-04-03 メディカル リサーチ ファンド アット ザ テル アビブ ソウラスキー メディカル センター 全身性炎症反応症候群（ｓｉｒｓ）の調節のための方法及び組成物
JP2013532654A (ja) * 2010-07-22 2013-08-19 サタナッシ，ダヴィード 毒ヘビの咬傷に対する解毒剤

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US4657761A (en) * 1985-06-05 1987-04-14 Pinto Cesar M Polyvalent non-specific immuno-stimulating vaccine and method
US4741902A (en) * 1986-07-14 1988-05-03 Haast William E Compositions for treatment of neurological and related disorders
US4806346A (en) * 1986-12-16 1989-02-21 American Home Products Corporation Method for isolation of antigen specific immunoglobulin
US5164196A (en) * 1987-05-19 1992-11-17 Ventech Research, Inc. Crotoxin complex as cytotoxic agent
US5232695A (en) * 1987-12-23 1993-08-03 G. D. Searle & Co. Method of ameliorating herpes simplex virus infections using purified nerve growth factor
US4877741A (en) * 1988-10-24 1989-10-31 The United States Of America As Represented By The Secretary Of The Air Force Treatment of human plasma with brown recluse spider toxin to emulate a lupus anticoagulant
US5196403A (en) * 1989-01-27 1993-03-23 Biogen, Inc. Method of inhibiting platelet activation
US5182260A (en) * 1989-01-27 1993-01-26 Biogen, Inc. Dna sequences encoding snake venom inhibitors of platelet activation processes for producing those inhibitors and compositions using them
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5242810A (en) * 1990-12-07 1993-09-07 Biogen, Inc. Bifunctional inhibitors of thrombin and platelet activation
US5863954A (en) * 1992-06-30 1999-01-26 John B. Davidson Contraceptive method using ajoene
CA2076944A1 (en) * 1992-06-30 1993-12-31 Alexander V. Tatarintsev Ajoene as an agent for inhibiting symptoms and growth of aids virus and changes at the cellular level
US6177475B1 (en) 1992-06-30 2001-01-23 Billings Pharmaceuticals, Inc. Methods of using integrin modulators for treatment of inflammation
US5981602A (en) * 1992-06-30 1999-11-09 John B. Davidson Methods of using Ajoene for inhibiting integrin-mediated cell-cell fusion
US5863955A (en) * 1992-06-30 1999-01-26 John B. Davidson Methods of using ajoene to inhibit an immune response
US5856363A (en) * 1992-06-30 1999-01-05 John B. Davidson Methods of using ajoene
US5948821A (en) * 1992-06-30 1999-09-07 John B. Davidson Methods of using ajoene
US5676974A (en) * 1992-10-23 1997-10-14 Santiago H. Valdes Pharmaceutical compositions containing giroxina and phospholipase A2 and methods of increasing a patient's CD4 count using the pharmaceutical compositions
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
ATE301472T1 (de) * 1994-03-31 2005-08-15 Biomed Comm Inc Wachstumsfaktoren enthaldende therapeutische homöopathische verdünnungen und verwendung
US6316602B1 (en) * 1994-05-03 2001-11-13 Binie V. Lipps Beta taipoxin as a cell growth factor and method
FR2769226B1 (fr) * 1997-10-06 2000-06-02 Centre Nat Rech Scient Utilisation des bloqueurs des canaux potassium dans le traitement des maladies neurologiques
SE0003619L (sv) * 1999-12-28 2001-08-23 Bjoern Oertenheim Farmaceutisk komposition och metod för dess framställning
US7045663B2 (en) * 2001-07-10 2006-05-16 Billings Pharmaceuticals, Inc. Chiral integrin modulators and methods of use thereof
EP1391207A1 (en) * 2001-04-24 2004-02-25 Luis Alberto Costa Use of a phospholipase a2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
CA2476765A1 (en) * 2002-02-21 2003-09-04 Quark Biotech, Inc. Methods of preventing or treating brain ischemia or brain injury
BG65618B1 (bg) * 2003-01-22 2009-03-31 Борис Алексиев Използване на противозмийски серум за лечение на мозъчен инсулт
WO2005014849A2 (en) * 2003-07-03 2005-02-17 Euro-Celtique, S.A. Genes associated with responses to neuropathic pain
US20050255097A1 (en) * 2004-01-26 2005-11-17 Paul Reid Modified venom and venom components as anti-retroviral agents
EP1737816A1 (en) * 2004-03-10 2007-01-03 Billings Pharmaceuticals, Inc. Integrin modulators and methods for their use
US20060034823A1 (en) * 2004-08-13 2006-02-16 Paul Reid Method of production and use of crotoxin as an analgesic
US20060045875A1 (en) * 2004-09-02 2006-03-02 Reid Paul F Method of use of crotoxin as an anti-retroviral agent
US8034777B2 (en) * 2004-09-23 2011-10-11 Receptopharm, Inc. Modified anticholinergic neurotoxins as modulators of the autoimmune reaction
US20060088858A1 (en) * 2004-10-25 2006-04-27 Reid Paul F Modified venom and venom components as anti-retroviral agents
US20060088843A1 (en) * 2004-10-25 2006-04-27 Reid Paul F Modified venom and venom components as anti-retroviral agents
DE102004055891B4 (de) 2004-11-19 2007-08-30 Wiesner, Henning, Prof., Dr. Gemische von Schlangengiften zur Krankheitsbekämpfung
GB0516586D0 (en) * 2005-08-12 2005-09-21 Smith & Nephew Ultrasound therapy for diabetic peripheral neuropathy
US7902152B2 (en) * 2005-12-20 2011-03-08 Receptopharm, Inc. Use of cobratoxin as an analgesic
US20070148159A1 (en) * 2005-12-22 2007-06-28 Reid Paul F Use of crotoxin as an analgesic - CIP
US7758894B2 (en) * 2006-11-06 2010-07-20 Receptopharm, Inc. Modified elapid venoms as stimulators of the immune reaction
US20090209468A1 (en) * 2006-12-19 2009-08-20 Reid Paul F Alpha-neurotoxin proteins with anti-inflammatory properties and uses thereof
US7259237B1 (en) * 2006-12-29 2007-08-21 Miller Kent D Pan-antiviral peptides
TR200708925A1 (tr) * 2007-12-26 2009-07-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan flurbiprofen ve kas gevşetici kombinasyonları
WO2009131435A1 (en) * 2008-04-23 2009-10-29 Erasmus University Medical Center Rotterdam Linker containing bungarotoxin and a binding peptide
US9220743B2 (en) * 2010-01-22 2015-12-29 Nuovo Biologics, Llc Pan-antiviral peptides for protein kinase inhibition
WO2018106062A1 (ko) * 2016-12-09 2018-06-14 아주대학교산학협력단 Ap 또는 ｎｍ를 포함하는 염증성 질환의 예방 또는 치료용 조성물
KR101802515B1 (ko) 2016-12-09 2017-11-29 아주대학교산학협력단 Ａｐ를 포함하는 염증성 질환의 예방 또는 치료용 조성물
US20220362356A1 (en) * 2019-07-02 2022-11-17 Dnbio Pharm, Inc. Composition For Preventing Or Treating Rheumatoid Arthritis, Comprising Snake Venom
KR102340531B1 (ko) * 2019-07-02 2021-12-21 독립바이오제약(주) Agkistrodon piscivorous piscivorous로부터 유래된 뱀독을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4012502A (en) * 1973-09-21 1977-03-15 Buren Philpot V Jun Snake venom inhibitor material and method of purification
US4126676A (en) * 1977-07-22 1978-11-21 Sanders Murray J Modified neurotoxin derived from naja genus snake venom
US4292308A (en) * 1979-08-21 1981-09-29 Biotherapeutics, Inc. Treatment of animals exposed to or subject to exposure to organophosphate animal poisonous nerve agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6333334A (ja) * 1986-05-19 1988-02-13 ベンテツク　リサーチ　インコーポレーテツド 細胞毒性薬剤としてのクロトキシン錯体
JP2008509990A (ja) * 2004-08-16 2008-04-03 メディカル リサーチ ファンド アット ザ テル アビブ ソウラスキー メディカル センター 全身性炎症反応症候群（ｓｉｒｓ）の調節のための方法及び組成物
JP2013532654A (ja) * 2010-07-22 2013-08-19 サタナッシ，ダヴィード 毒ヘビの咬傷に対する解毒剤

Also Published As

Publication number Publication date
EP0063091A2 (en) 1982-10-20
MX7262E (es) 1988-03-03
DE3273730D1 (en) 1986-11-20
IL65405A (en) 1985-06-30
EP0063091A3 (en) 1983-06-22
IL65405A0 (en) 1982-07-30
US4341762A (en) 1982-07-27
EP0063091B1 (en) 1986-10-15

Similar Documents

Publication Publication Date Title
JPS57179120A (en) Application of snake poison for treatment of nervous system or related diseases
IL64001A0 (en) Blood treatment system
GB2096074B (en) Facilitating passage of wheelchairs over obstacles
DE2966594D1 (en) Electroencephalographic system for the quantitative description of patient brain states
GB2122496B (en) Method and apparatus for the treatment of autoimmune and allergic diseases
SG93587G (en) Treatment of water
AU8420882A (en) Electro-flocculation treatment of water
DE3263639D1 (en) Effluent treatment
IL65588A (en) Pharmaceutical compositions for the treatment of skin
DE3261704D1 (en) Apparatus for the application of acupuncture-type therapeutical treatments
EP0457671A3 (en) Dipyridamide for the treatment of diseases of the central or peripheral nervous system
JPS57174194A (en) Treatment of aqueous system
GB2093727B (en) Treatment of sludge
JPS56130480A (en) Corrosion prevention of apparatus made of titanium
ZA835997B (en) Treatment of zeolites
JPS57129893A (en) Treatment of waste fish
GB2110087B (en) Treatment of respiratory diseases
GB2103916B (en) Treatment of straw
JPS57149555A (en) Treatment of fiber
JPS57179493A (en) Drain discharger of gas system
EP0078533A3 (en) Medicinal composition for treating skin disorders
ZA823321B (en) Treatment of minimal brain dysfunction (mbd)
JPS57205645A (en) Method of treatment of spring water
AU538311B2 (en) Treatment of disorders of calcium metabolism
BG36215A1 (en) Means for treatment of gallic diseases